The present invention relates to leukotriene receptor antagonists, in particular zafirlukast and its derivatives, for use in the treatment of Gram-positive bacterial infections, wherein the bacterial infections are not a Mycobacterium or Corynebacterium infections, as well as pharmaceutical compositions comprising the same and corresponding methods of treatment.